Literature DB >> 12202229

Influenza A virus with defective M2 ion channel activity as a live vaccine.

Tokiko Watanabe1, Shinji Watanabe, Hiroshi Kida, Yoshihiro Kawaoka.   

Abstract

We propose a rational approach to the design of live virus vaccines against influenza infection by alteration of the influenza A virus M2 protein, which is responsible for ion channel activity. Previously we demonstrated that a mutant A/WSN/33 (H1N1) influenza virus with defective M2 ion channel activity did not show appreciable growth defects in cell culture, although its growth was attenuated in mice (T. Watanabe, S. Watanabe, H. Ito, H. Kida, and Y. Kawaoka, 2001, J. Virol. 75, 5656-5662). Here, we show that this M2 ion channel defective mutant virus, the M2del29-31, protected mice against challenge with lethal doses of influenza virus, indicating the potential of incorporating this M2 alteration in a live influenza vaccine as one of the attenuating mutations.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12202229     DOI: 10.1006/viro.2002.1508

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  6 in total

1.  Activation of tumor antigen-specific cytotoxic T lymphocytes (CTLs) by human dendritic cells infected with an attenuated influenza A virus expressing a CTL epitope derived from the HER-2/neu proto-oncogene.

Authors:  Clay L Efferson; Jeanne Schickli; Byung Kyum Ko; Kouichiro Kawano; Sara Mouzi; Peter Palese; Adolfo García-Sastre; Constantin G Ioannides
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

2.  The new temperature-sensitive mutation PA-F35S for developing recombinant avian live attenuated H5N1 influenza vaccine.

Authors:  Wenting Zhang; Jiagang Tu; Zongzheng Zhao; Huanchun Chen; Meilin Jin
Journal:  Virol J       Date:  2012-05-23       Impact factor: 4.099

Review 3.  Making better influenza virus vaccines?

Authors:  Peter Palese
Journal:  Emerg Infect Dis       Date:  2006-01       Impact factor: 6.883

Review 4.  The role of reverse genetics in the development of vaccines against respiratory viruses.

Authors:  G A Marsh; G A Tannock
Journal:  Expert Opin Biol Ther       Date:  2005-03       Impact factor: 4.388

5.  Confronting potential influenza A (H5N1) pandemic with better vaccines.

Authors:  Azizul Haque; Didier Hober; Lloyd H Kasper
Journal:  Emerg Infect Dis       Date:  2007-10       Impact factor: 6.883

Review 6.  Influenza vaccines: a moving interdisciplinary field.

Authors:  Michael Schotsaert; Adolfo García-Sastre
Journal:  Viruses       Date:  2014-10-09       Impact factor: 5.048

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.